Health
Freiburg immunologists decipher anti-cancer drug’s mode of operation – News-Medical.net
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University…
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works. A team headed by Professor Dr. Michael Reth used cell cultures, healthy cells, and cells from cancer patients to investigate how CD20 organizes the nanostructures on the B cell membrane. If the protein is missing or Rituximab binds to it, the organization of the B cell surface…
-
Noosa News20 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
Noosa News19 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
General23 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Business6 hours agoFord CEO makes stunning prediction about artificial intelligence